Latest news with #725
Economic Times
2 days ago
- Business
- Economic Times
ADIA signs a definitive agreement to invest $200 million in medical devices firm Meril
Abu Dhabi Investment Authority (ADIA) has signed a definitive agreement to invest $200 million (about Rs1,725 crore) for a 3% stake in medical devices maker Micro Life Sciences Pvt Ltd (Meril). The investment by a wholly-owned subsidiary of ADIA pegged Meril's enterprise valuation at $6.6 billion, the Vapi, Gujarat-based company said in a statement. Post the investment, Meril will be backed by two major global investors ADIA, and US private equity firm Warburg Pincus. The deal is subject to Competition Commission of India (CCI) approval. 'This investment by ADIA reinforces confidence in Meril's long-term vision and global ambitions,' said Sanjeev Bhatt, senior vice president-strategy at Meril. 'This investment will enable us to accelerate growth, attract world-class talent, and further strengthen clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions.' Meril was founded in 2006 by the Bilakhia Group after divesting their agrochemical business to Bayer, and the Micro lnks business to Hubergroup—both from Germany. In 2022, the promoters tapped Warburg Pincus to raise Rs 1,575 crore by selling a 14% stake in Meril, and Rohit Kothari's Anchorage Capital for Rs 200 crore by divesting a 2% stake at a valuation of about Rs 11,000 crore. In the three years since, Meril closed fundraisings for another 3% shareholdings while its valuation surged more than fivefold to nearly Rs 60,000 crore. The Bilakhia family currently has more than 81% stake in the company, with Warburg, ADIA, and Kothari being other principal shareholders together holding nearly 19%.Meril is regarded as an innovator in medical technology (MedTech), with a focus on clinically-advanced solutions across multiple specialties such as cardiovascular, structural heart, orthopaedics, endo-surgery, in-vitro diagnostics and surgical robotics. Some of the innovations include transcatheter heart valve series, transcatheter edge-to-edge repair system, and surgical robotic system. The company is growing between 30-35% compounded annually, with FY25 revenue at Rs 4,800 crore and margins of 27-28%. Exports contributed about 55% of expect the company to double revenue within less than three years. Meril employs more than 13,000 employees and has over 35 global subsidiaries. Its Vapi facility spans over 100 acres with over 1 million sq ft manufacturing space.
Time of India
2 days ago
- Business
- Time of India
ADIA signs a definitive agreement to invest $200 million in medical devices firm Meril
Abu Dhabi Investment Authority (ADIA) is set to invest $200 million for a 3% stake in medical device maker Meril, valuing the company at $6.6 billion. This investment, pending CCI approval, will support Meril's growth and research efforts. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Abu Dhabi Investment Authority (ADIA) has signed a definitive agreement to invest $200 million (about Rs1,725 crore) for a 3% stake in medical devices maker Micro Life Sciences Pvt Ltd ( Meril ).The investment by a wholly-owned subsidiary of ADIA pegged Meril's enterprise valuation at $6.6 billion, the Vapi, Gujarat-based company said in a the investment, Meril will be backed by two major global investors ADIA, and US private equity firm Warburg Pincus . The deal is subject to Competition Commission of India (CCI) approval.'This investment by ADIA reinforces confidence in Meril's long-term vision and global ambitions,' said Sanjeev Bhatt, senior vice president-strategy at Meril. 'This investment will enable us to accelerate growth, attract world-class talent, and further strengthen clinical research efforts as we work towards improving the quality of human life through advanced healthcare solutions .'Meril was founded in 2006 by the Bilakhia Group after divesting their agrochemical business to Bayer, and the Micro lnks business to Hubergroup—both from 2022, the promoters tapped Warburg Pincus to raise Rs 1,575 crore by selling a 14% stake in Meril, and Rohit Kothari's Anchorage Capital for Rs 200 crore by divesting a 2% stake at a valuation of about Rs 11,000 crore. In the three years since, Meril closed fundraisings for another 3% shareholdings while its valuation surged more than fivefold to nearly Rs 60,000 Bilakhia family currently has more than 81% stake in the company, with Warburg, ADIA, and Kothari being other principal shareholders together holding nearly 19%.Meril is regarded as an innovator in medical technology (MedTech), with a focus on clinically-advanced solutions across multiple specialties such as cardiovascular, structural heart, orthopaedics, endo-surgery, in-vitro diagnostics and surgical robotics. Some of the innovations include transcatheter heart valve series, transcatheter edge-to-edge repair system, and surgical robotic company is growing between 30-35% compounded annually, with FY25 revenue at Rs 4,800 crore and margins of 27-28%. Exports contributed about 55% of expect the company to double revenue within less than three employs more than 13,000 employees and has over 35 global subsidiaries. Its Vapi facility spans over 100 acres with over 1 million sq ft manufacturing space.
Economic Times
10-07-2025
- Business
- Economic Times
Laurus Labs shares zoom 19% to hit new all-time high. Is there more heat left?
Laurus Labs stock's recent breakout above the Rs 720–Rs 725 range seems to be a key driver behind its bullish momentum. Laurus Labs surged over 19% in 11 days, hitting a record high of Rs 799.4. Analysts see strong bullish momentum supported by a multi-year breakout, volume patterns, and technical indicators, but advise caution for fresh buyers due to overbought conditions and potential profit-booking zones. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Laurus Labs shares have seen an impressive 19.35% surge in the last 11 days, reaching a new all-time high of Rs 799.4 today on the BSE. This rally has sparked significant investor interest, with technical analysts offering positive insights on the stock's performance and its future stock's recent breakout above the Rs 720–Rs 725 range seems to be a key driver behind its bullish Laurus Labs continues its strong upward trajectory, experts are weighing in on how to approach trading at these elevated levels. While some analysts remain bullish, they also caution investors to be strategic, with key support levels and potential profit-taking zones to Tejas Shah, Senior Vice President of Technical Research at JM Financial Services, Laurus Labs has experienced a multi-year breakout above the Rs 720–Rs 725 levels, sparking a sharp highlighted that this uptrend is supported by increasing volumes during gains and tapering volumes on declines, which is considered a classic sign of healthy stock continues to trade above its 50-day Exponential Moving Average (EMA), reinforcing the positive trend. Mr. Shah further highlighted the emergence of an Ascending Triangle pattern on the weekly chart, which validates the breakout.(Source: JM Financial)The overall chart structure appears strong, and with the relative strength of the stock and favorable sector tailwinds, Laurus Labs is positioned as a strong outperformer in the near to medium expects the stock to potentially move towards Rs 890 and Rs 945 over the next 6 to 12 months, with key support seen in the Rs 720–Rs 725 Gour, Senior Technical Analyst at Swastika Investmart , also weighed in on the stock's strong uptrend, noting that Laurus Labs has made a significant move from the Rs 650–Rs 700 range, showing clear stock is trading above all key moving averages, and the steep upward slope of the 20-SMA and 50-SMA signals strong short-term momentum. Furthermore, the Moving Average Convergence Divergence (MACD) and the Relative Strength Index (RSI) remain in favour of the stock's bullish existing shareholders, Gour advises trailing the stop-loss below the 9-SMA (Rs 755) to protect profits. He also suggests partial profit booking in the Rs 820–Rs 850 zone if momentum starts to slow potential new entrants, however, he cautions against aggressive fresh buying at current levels due to the overbought RSI. Instead, he recommends waiting for a retest of the Rs 755–Rs 770 levels or looking for bullish candle confirmation on lower time-frames before entering the technical outlook for Laurus Labs suggests a strong uptrend, with bullish momentum supported by solid chart structures and favourable sector conditions. While the stock has shown impressive growth recently, analysts recommend a cautious approach for new buyers at current levels.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Time of India
10-07-2025
- Business
- Time of India
Laurus Labs shares zoom 19% to hit new all-time high. Is there more heat left?
Laurus Labs shares have seen an impressive 19.35% surge in the last 11 days, reaching a new all-time high of Rs 799.4 today on the BSE. This rally has sparked significant investor interest, with technical analysts offering positive insights on the stock's performance and its future potential. The stock's recent breakout above the Rs 720–Rs 725 range seems to be a key driver behind its bullish momentum. As Laurus Labs continues its strong upward trajectory, experts are weighing in on how to approach trading at these elevated levels. While some analysts remain bullish, they also caution investors to be strategic, with key support levels and potential profit-taking zones identified. According to Tejas Shah, Senior Vice President of Technical Research at JM Financial Services, Laurus Labs has experienced a multi-year breakout above the Rs 720–Rs 725 levels, sparking a sharp rally. He highlighted that this uptrend is supported by increasing volumes during gains and tapering volumes on declines, which is considered a classic sign of healthy accumulation. The stock continues to trade above its 50-day Exponential Moving Average (EMA), reinforcing the positive trend. Mr. Shah further highlighted the emergence of an Ascending Triangle pattern on the weekly chart, which validates the breakout. (Source: JM Financial) The overall chart structure appears strong, and with the relative strength of the stock and favorable sector tailwinds, Laurus Labs is positioned as a strong outperformer in the near to medium term. He expects the stock to potentially move towards Rs 890 and Rs 945 over the next 6 to 12 months, with key support seen in the Rs 720–Rs 725 range. Also read: Q1 results season begins: Pace of downgrades may slowdown. Top Nifty, midcap, smallcap stock ideas Pravesh Gour, Senior Technical Analyst at Swastika Investmart , also weighed in on the stock's strong uptrend, noting that Laurus Labs has made a significant move from the Rs 650–Rs 700 range, showing clear momentum. The stock is trading above all key moving averages, and the steep upward slope of the 20-SMA and 50-SMA signals strong short-term momentum. Furthermore, the Moving Average Convergence Divergence (MACD) and the Relative Strength Index (RSI) remain in favour of the stock's bullish momentum. For existing shareholders, Gour advises trailing the stop-loss below the 9-SMA (Rs 755) to protect profits. He also suggests partial profit booking in the Rs 820–Rs 850 zone if momentum starts to slow down. For potential new entrants, however, he cautions against aggressive fresh buying at current levels due to the overbought RSI. Instead, he recommends waiting for a retest of the Rs 755–Rs 770 levels or looking for bullish candle confirmation on lower time-frames before entering the stock. The technical outlook for Laurus Labs suggests a strong uptrend, with bullish momentum supported by solid chart structures and favourable sector conditions. While the stock has shown impressive growth recently, analysts recommend a cautious approach for new buyers at current levels. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Yahoo
15-05-2025
- Business
- Yahoo
CRAI Q1 Earnings Call: Broad-Based Growth, Robust Antitrust Demand, and Steady Guidance
Economic consulting firm CRA International (NASDAQ:CRAI) reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 5.9% year on year to $181.9 million. The company's full-year revenue guidance of $725 million at the midpoint came in 0.9% above analysts' estimates. Its non-GAAP profit of $2.22 per share was 13.8% above analysts' consensus estimates. Is now the time to buy CRAI? Find out in our full research report (it's free). Revenue: $181.9 million vs analyst estimates of $176.6 million (5.9% year-on-year growth, 3% beat) Adjusted EPS: $2.22 vs analyst estimates of $1.95 (13.8% beat) Adjusted EBITDA: $24.79 million vs analyst estimates of $22.1 million (13.6% margin, 12.2% beat) The company reconfirmed its revenue guidance for the full year of $725 million at the midpoint Operating Margin: 14%, up from 11.4% in the same quarter last year Free Cash Flow was -$80.97 million compared to -$63.81 million in the same quarter last year Market Capitalization: $1.27 billion CRA International's first quarter results were shaped by broad-based contributions across key practices and geographies. Management attributed revenue growth to double-digit expansion in its Energy, Finance, Intellectual Property, and Life Sciences practices, with the Antitrust & Competition Economics group achieving a new revenue high. CEO Paul Maleh highlighted the acceleration of project lead flow through the quarter, noting that consulting utilization improved and that performance was supported by international operations, which saw nearly 20% year-on-year growth. Looking ahead, management reaffirmed its full-year revenue guidance, citing continued momentum in new business origination and a replenished sales pipeline. Maleh cautioned that while March's positive trends continued into April, it remains too early to assume these trends will persist throughout the year, given ongoing macroeconomic and geopolitical uncertainty. He added that CRA remains focused on optimizing its service portfolio and aligning headcount growth with revenue opportunities. CRA International's management pointed to multiple factors driving Q1 performance, emphasizing practice diversification, geographic expansion, and a steady demand environment. The company's results exceeded analysts' expectations, aided by improved consulting utilization and project origination. Antitrust practice momentum: The Antitrust & Competition Economics group reached record quarterly revenue, fueled by ongoing demand for merger-related and antitrust advisory work, including high-profile projects such as supporting Microsoft in regulatory matters. International growth contributions: International operations delivered nearly 20% year-on-year revenue growth, with management citing a balanced portfolio across North America and global markets as key to consistent performance. Collaborative client delivery: Management highlighted increased collaboration across practices and geographies, enabling the firm to address complex, multi-jurisdictional projects involving litigation, M&A, and regulatory compliance. Life Sciences and Energy strength: The Life Sciences practice extended its turnaround, posting another strong quarter across opportunity assessment and launch planning, while Energy consulting saw double-digit revenue gains through projects in strategy, risk, and transaction support. Service portfolio optimization: The company completed targeted restructuring affecting 15 roles, intended to align resources with areas of higher growth potential. Management emphasized ongoing investment in talent acquisition and retention to support future expansion. Management's outlook for the remainder of the year centers on sustained demand for legal, regulatory, and management consulting services, tempered by an awareness of economic and geopolitical uncertainties that could affect client activity. Sales pipeline health: Continued growth in project lead flow and new project originations underpins management's confidence in meeting guidance, though they acknowledge that business inflow can be sensitive to shifts in client sentiment. Practice diversification: The company's broad mix of practices—spanning antitrust, finance, energy, and life sciences—positions it to capture growth across multiple sectors, reducing reliance on any single client or industry vertical. Headcount and talent alignment: Ongoing investments in hiring and talent retention are expected to keep consultant headcount roughly in line with revenue growth, supporting utilization rates and client delivery capabilities. Andrew Nicholas (William Blair): Asked how recent April trends influence confidence in guidance; CEO Maleh said March's momentum continued but noted it is too early to assume these trends will persist. Andrew Nicholas (William Blair): Queried about the Life Sciences pipeline; Maleh stated the practice is seeing broad success geographically and across service areas, hoping for continued momentum. Andrew Nicholas (William Blair): Sought clarification on headcount plans and retention; Maleh explained that headcount remains flat sequentially, with ongoing investments in both new hires and retaining talent. Marc Riddick (Sidoti & Company): Asked if recent business acceleration was tied to external events; Maleh said no single driver was identifiable, attributing growth to a diversified portfolio. Kevin Steinke (Barrington Research): Inquired about restructuring; Maleh clarified the move was a targeted optimization, not a reflection of overall practice health. In the coming quarters, the StockStory team will be monitoring (1) whether growth in project origination and sales pipeline leads to consistent revenue expansion, (2) if utilization rates remain elevated as consultant headcount adjusts to business needs, and (3) further momentum within high-performing practices such as Antitrust & Competition Economics, Energy, and Life Sciences. Talent acquisition and retention efforts, as well as the firm's ability to adapt to external market conditions, will remain important areas of focus. CRA currently trades at a forward P/E ratio of 23.3×. At this valuation, is it a buy or sell post earnings? Find out in our free research report. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
